Shashikant Srivastava

ORCID

Publication Activity (10 Years)

Years Active: 2020-2023
Publications (10 Years): 15

Top Venues

Antimicrobial agents and chemotherapy

Open forum infectious diseases

PloS one

The University of Texas Health Science Center at Tyler

Babasaheb Bhimrao Ambedkar University (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

The University of Texas Health Science Center at Tyler Apr 01 2020

United States

Associate Professor of Pulmonary Immunology :: Pulmonary Immunology

Texas Tech University Health Sciences Center Aug 01 2019 - Feb 28 2020

United States

Associate Professor :: Pharmacy Practice

Baylor Institute for Immunology Research - Jul 31 2019

United States

Assistant Investigator :: CIDRET

University of Texas Southwestern Medical Center Jan 26 2008 - Nov 14 2014

United States

Assistant Professor :: Immunology

Education History

Babasaheb Bhimrao Ambedkar University

India

PHD

Publications

Sanjay Singh, Tawanda Gumbo, Gunavanthi D Boorgula, Tania A Thomas, Julie V Philley, Shashikant Srivastava
Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model. Antimicrobial agents and chemotherapy 68 (2) (2023)
Shashikant Srivastava, Tawanda Gumbo
Comment on "Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections". Open forum infectious diseases 10 (8) (2023)
Sanjay Singh, Tawanda Gumbo, Gunavanthi D Boorgula, Tania A Thomas, Julie V Philley, Shashikant Srivastava
Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model. Antimicrobial agents and chemotherapy 68 (2) (2023)
Sanjay Singh, Tawanda Gumbo, Gunavanthi D Boorgula, Tania A Thomas, Julie V Philley, Shashikant Srivastava
Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model. Antimicrobial agents and chemotherapy 68 (2) (2023)
Sanjay Singh, Tawanda Gumbo, Gunavanthi D Boorgula, Tania A Thomas, Julie V Philley, Shashikant Srivastava
Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model. Antimicrobial agents and chemotherapy 68 (2) (2023)
Sanjay Singh, Tawanda Gumbo, Gunavanthi D Boorgula, Tania A Thomas, Julie V Philley, Shashikant Srivastava
Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model. Antimicrobial agents and chemotherapy 68 (2) (2023)
Sanjay Singh, Tawanda Gumbo, Gunavanthi D Boorgula, Tania A Thomas, Julie V Philley, Shashikant Srivastava
Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model. Antimicrobial agents and chemotherapy (2023)
Sanjay Singh, Tawanda Gumbo, Gunavanthi D Boorgula, Tania A Thomas, Julie V Philley, Shashikant Srivastava
Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model. Antimicrobial agents and chemotherapy 68 (2) (2023)
Sanjay Singh, Tawanda Gumbo, Gunavanthi D Boorgula, Tania A Thomas, Julie V Philley, Shashikant Srivastava
Omadacycline pharmacokinetics/pharmacodynamics and efficacy against multidrug-resistant Mycobacterium tuberculosis in the hollow fiber system model. Antimicrobial agents and chemotherapy 68 (2) (2023)
Sanjay Singh, Tawanda Gumbo, Gunavanthi D Boorgula, Prem Shankar, Scott K Heysell, Shashikant Srivastava
Omadacycline Pharmacokinetics/Pharmacodynamics in the Hollow Fiber System Model and Potential Combination Regimen for Short Course Treatment of Mycobacterium kansasii Pulmonary Disease. Antimicrobial agents and chemotherapy 66 (9) (2022)
Shashikant Srivastava, Gunavanthi D Boorgula, Ming-Chia Lee, Hung-Ling Huang, Dave Howe, Tawanda Gumbo, Scott K Heysell
Rifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection. Antimicrobial agents and chemotherapy 66 (4) (2022)
Shashikant Srivastava, Jann-Yuan Wang, Gesham Magombedze, Moti Chapagain, Hung-Ling Huang, Devyani Deshpande, Scott K Heysell, Jotam G Pasipanodya, Tawanda Gumbo
Nouveau short-course therapy and morphism mapping for clinical pulmonary Mycobacterium kansasii. Antimicrobial agents and chemotherapy (2021)
Suresh Mallikaarjun, Moti L Chapagain, Tomohiro Sasaki, Norimitsu Hariguchi, Devyani Deshpande, Shashikant Srivastava, Alexander Berg, Kuniko Hirota, Yusuke Inoue, Makoto Matsumoto, Jeffrey Hafkin, Lawrence Geiter, Xiaofeng Wang, Tawanda Gumbo, Yongge Liu
Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis. Antimicrobial agents and chemotherapy 65 (1) (2020)
Moti Chapagain, Tawanda Gumbo, Scott K Heysell, Shashikant Srivastava
Comparison of a Novel Regimen of Rifapentine, Tedizolid, and Minocycline with Standard Regimens for Treatment of Pulmonary Mycobacterium kansasii. Antimicrobial agents and chemotherapy 64 (10) (2020)
Shashikant Srivastava, Moti Chapagain, Tawanda Gumbo
Effect of specimen processing, growth supplement, and different metabolic population on Mycobacterium tuberculosis laboratory diagnosis. PloS one 15 (4) (2020)

Shashikant Srivastava.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Shashikant Srivastava